RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재

      사이토카인과 우울증 = Cytokines and Depression

      한글로보기

      https://www.riss.kr/link?id=A101640963

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Accumulating evidence has suggested the existence of reciprocal communication between immune, endocrine, and neurotransmitter system. Cytokine hypothesis of depression implies that increased pro-inflammatory cytokine such as -1, IL-6, IL-12, TNF-${\alpha}$, and IFN-${\gamma}$ in major depression, acting neuromodulators, play a key role in the mediation of behavioral, neuroendocrine, and neurochemical disturbances in depression. Concerning the relation between cytokines and serotonin metabolism, pro-inflammatory cytokines have profound effects on the metabolism of brain serotonin through the enzyme indoleamine-2,3-dioxygenase(IDO) that metabolizes tryptophan, the precursor of 5-HT to neurodegenerative quinolinate and neuroprotective kynurenate. The neurodegeneration process is reinforced by the neurotoxic effect of the hypercortisolemia during depression. From this perspective, it is possible that efficacy of antidepressants in the treatment of depression may, at least in part, rely on downregulation of pro-inflammatory cytokine synthesis. So, the use of cytokine synthesis inhibitors or cytokine antagonists may be a new treatment approach in depression. However, at present the question whether cytokines play a causal role in the onset of depression or are mere epiphenomena sustaining depressive symptoms remains to be elucidated. Nevertheless, cytokine hypothesis has created new perspectives in the study of psychological and pathophysiological mechanism that are associated with major depression, as well as the prospect for developing a new generation antidepressants.
      번역하기

      Accumulating evidence has suggested the existence of reciprocal communication between immune, endocrine, and neurotransmitter system. Cytokine hypothesis of depression implies that increased pro-inflammatory cytokine such as -1, IL-6, IL-12, TNF-${\al...

      Accumulating evidence has suggested the existence of reciprocal communication between immune, endocrine, and neurotransmitter system. Cytokine hypothesis of depression implies that increased pro-inflammatory cytokine such as -1, IL-6, IL-12, TNF-${\alpha}$, and IFN-${\gamma}$ in major depression, acting neuromodulators, play a key role in the mediation of behavioral, neuroendocrine, and neurochemical disturbances in depression. Concerning the relation between cytokines and serotonin metabolism, pro-inflammatory cytokines have profound effects on the metabolism of brain serotonin through the enzyme indoleamine-2,3-dioxygenase(IDO) that metabolizes tryptophan, the precursor of 5-HT to neurodegenerative quinolinate and neuroprotective kynurenate. The neurodegeneration process is reinforced by the neurotoxic effect of the hypercortisolemia during depression. From this perspective, it is possible that efficacy of antidepressants in the treatment of depression may, at least in part, rely on downregulation of pro-inflammatory cytokine synthesis. So, the use of cytokine synthesis inhibitors or cytokine antagonists may be a new treatment approach in depression. However, at present the question whether cytokines play a causal role in the onset of depression or are mere epiphenomena sustaining depressive symptoms remains to be elucidated. Nevertheless, cytokine hypothesis has created new perspectives in the study of psychological and pathophysiological mechanism that are associated with major depression, as well as the prospect for developing a new generation antidepressants.

      더보기

      참고문헌 (Reference)

      1 Maes M., "monocyte-T-lymphocyte hypothesis of major depression" 20 : 111-116, 1995

      2 Cserr HF., "ervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view" 13 : 507-512, 1992

      3 Beattie EC., "Von Zastrow M, et al. Control of synaptic strength by glial TNFalpha" 295 : 2282-2285, 2002

      4 Xia Z., "Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells" 34 : 27-37, 1996

      5 Capuron L., "Treatment of cytokine-induced depression" 16 : 575-580, 2002

      6 Munoz-Fernandez MA., "The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system" 56 : 307-340, 1998

      7 Licinio J., "The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection" 4 : 317-327, 1999

      8 Kim YK., "The role of cytokine network in psychological stress" 15 : 148-155, 2003

      9 Lee KM, "The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder" 6 : 1298-1304, 2006

      10 Kasper S., "The rationale for long-term antidepressant therapy" 8 : 225-235, 1993

      1 Maes M., "monocyte-T-lymphocyte hypothesis of major depression" 20 : 111-116, 1995

      2 Cserr HF., "ervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view" 13 : 507-512, 1992

      3 Beattie EC., "Von Zastrow M, et al. Control of synaptic strength by glial TNFalpha" 295 : 2282-2285, 2002

      4 Xia Z., "Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells" 34 : 27-37, 1996

      5 Capuron L., "Treatment of cytokine-induced depression" 16 : 575-580, 2002

      6 Munoz-Fernandez MA., "The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system" 56 : 307-340, 1998

      7 Licinio J., "The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection" 4 : 317-327, 1999

      8 Kim YK., "The role of cytokine network in psychological stress" 15 : 148-155, 2003

      9 Lee KM, "The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder" 6 : 1298-1304, 2006

      10 Kasper S., "The rationale for long-term antidepressant therapy" 8 : 225-235, 1993

      11 Kim YK., "The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs" 7 : 1107-1114, 2002

      12 Smith RS, "The macrophage theory of depression" 35 : 298-306, 1991

      13 Tracey KJ., "The inflammatory reflex" 420 : 853-859, 2002

      14 Leonard BE, "The immune system, depression and the action of antidepressants" 25 : 767-780, 2001

      15 Muller N., "The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine" 11 : 680-684, 2006

      16 Schildkraut JJ., "The catecholamine hypothesis of affective disorders: a review of supporting evidence" 122 : 509-522, 1965

      17 Camara EG., "The brain and the immune system: a psychosomatic network" 30 : 140-146, 1989

      18 Myint AM, "Th1, Th2, and Th3 cytokine alterations in major depression" 88 : 167-173, 2005

      19 Watanabe Y., "Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons" 588 : 341-345, 1992

      20 Luine VN., "Steroid hormone influences on spatial memory" 743 : 201-211, 1994

      21 Muller N., "Role of the cytokine network in the CNS and psychiatric disorders" 68 : 11-20, 1997

      22 Nabriski D., "Role of corticotropin-releasing factor in immunosuppression" 104 : 238-247, 1991

      23 Maes M., "Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression" 49 : 11-27, 1993

      24 Charney DS, "Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression" 38 : 1160-1180, 1981

      25 de Beaurepaire R., "Questions raised by the cytokine hypothesis of depression" 16 : 610-617, 2002

      26 Ader R., "Psychoneuroimmunology: interactions between the nervous system and the immune system" 345 : 99-103, 1995

      27 Solomon GF., "Psychoneuroimmunology: interactions between central nervous system and immune system" 18 : 1-9, 1987

      28 Whyte EM., "Post stroke depression: epidemiology, pathophysiology, and biological treatment" 52 : 253-264, 2002

      29 Young SN., "Pihl RO Ervin FR. Tryptophan depletion causes a rapid lowering of mood in normal males" 87 : 173-177, 1985

      30 Gutman DA, "Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies" 79 : 471-478, 2003

      31 Maes M., "Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion" 20 : 370-379, 1999

      32 Meyers CA, "Mood and cognitive disorders in cancer patients receiving cytokine therapy" 461 : 75-81, 1999

      33 Dantzer R., "Mechanisms of the behavioural effects of cytokines" 461 : 83-105, 1999

      34 Maes M., "Major depression and activation of the inflammatory response system" 461 : 25-46, 1999

      35 Pollmacher T., "Low levels of circulating inflammatory cytokines--do they affect human brain functions?" 16 : 525-532, 2002

      36 Wong ML., "Localization of interleukin-1 beta converting enzyme mRNA in rat brain vasculature: evidence that the genes encoding the interleukin-1 system are constitutively expressed in brain blood vessels. Pathophysiological implications" 2 : 141-148, 1995

      37 Myint AM., "Kynurenine pathway in major depression: evidence of impaired neuroprotection" 98 : 143-151, 2007

      38 Neveu PJ., "Is there evidence for an effect of antidepressant drugs on immune function?" 461 : 267-281, 1999

      39 Maier SF., "Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock" 695 : 279-282, 1995

      40 Sluzewska A., "Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine" 762 : 474-476, 1995

      41 Sapolsky R., "Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor" 238 : 522-524, 1987

      42 Breder CD., "Interleukin-1 immunoreactive innervation of the human hypothalamus" 240 : 321-324, 1988

      43 Suzuki E., "Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain" 215 : 201-204, 1996

      44 Bauer J., "Induction of cytokine synthesis and fever suppresses REM sleep and improves mood in patients with major depression" 38 : 611-621, 1995

      45 Wong ML., "Inducible nitric oxide synthase gene expression in the brain during systemic inflammation" 2 : 581-584, 1996

      46 Maes M., "Increased serum interleukin-1-receptor-antagonist concentrations in major depression" 36 : 29-36, 1995

      47 Guillemin GJ., "IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment" 21 : 1097-1101, 2001

      48 Irwin MR., "Human psychoneuroimmunology: 20 years of discover" 22 : 129-139, 2008

      49 Leonard BE., "HPA and immune axes in stress: involvement of the serotonergic system" 13 : 268-276, 2006

      50 Maes M., "Evidence for an immune response in major depression: a review and hypothesis" 19 : 11-38, 1995

      51 Shopsin B., "Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: a rational treatment approach" 4 : 188-192, 1978

      52 Miller AH., "Effects of cytokines on glucocorticoid receptor expression and function" 461 : 107-116, 1999

      53 Castanon N., "Effects of antidepressants on cytokine production and actions" 16 : 569-574, 2002

      54 Myint AM, "Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression" 14 : 65-71, 2007

      55 Lacroix S., "Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain" 70 : 452-466, 1998

      56 Watkins LR., "Dynamic regulation of proinflammatory cytokines" 461 : 153-178, 1999

      57 Kim YK, "Differences in cytokines between non-suicidal patients and suicidal patients in major depression" 32 : 356-361, 2008

      58 Connor TJ., "Depression, stress and immunological activation: the role of cytokines in depressive disorders" 62 : 583-606, 1998

      59 Stommel M., "Depression and functional status as predictors of death among cancer patients" 94 : 2719-2727, 2002

      60 Edwards E., "Depression and Parkinson's disease: a new look at an old problem" 16 : 39-48, 2002

      61 Anderson IM., "Decreased plasma tryptophan concentration in major depression: relationship to melancholia and weight loss" 20 : 185-191, 1990

      62 Anisman H., "Cytokines, stress, and depressive illness" 16 : 513-524, 2002

      63 Sakash JB., "Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection" 70 : 3959-3961, 2002

      64 Maier SF., "Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition" 105 : 83-107, 1998

      65 Rothwell NJ, "Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology" 69 : 85-95, 1996

      66 Szelenyi J., "Cytokines and the central nervous system" 54 : 329-338, 2001

      67 Schiepers OJ., "Cytokines and major depression" 29 : 201-217, 2005

      68 Zalcman S., "Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6" 643 : 40-49, 1994

      69 Myint AM, "Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression" 61 : 519-525, 2003

      70 Pollak Y., "Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment" 5 : 389-399, 2002

      71 Aloisi F., "Cytokine regulation of astrocyte function: in-vitro studies using cells from the human brain" 13 : 265-274, 1995

      72 Weizman R., "Cytokine production in major depressed patients before and after clomipramine treatment" 35 : 42-47, 1994

      73 Kim YK., "Cytokine imbalance in the pathophysiology of major depressive disorder" 31 : 1044-1053, 2007

      74 Freidin M., "Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta" 89 : 10440-10443, 1992

      75 Berkenbosch F., "Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1" 238 : 524-526, 1987

      76 Leonard BE., "Changes in the immune system in rodent models of depression" 5 : 345-356, 2002

      77 Leonard BE., "Changes in the immune system in depression and dementia: causal or co-incidental effects?" 19 : 305-312, 2001

      78 Calogero AE., "Catecholamine effects upon rat hypothalamic corticotropin-releasing hormone secretion in vitro" 82 : 839-846, 1988

      79 Mansbach RS., "Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist" 323 : 21-26, 1997

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2026 평가예정 재인증평가 신청대상 (재인증)
      2020-01-01 평가 등재학술지 유지 (재인증) KCI등재
      2017-01-01 평가 등재학술지 유지 (계속평가) KCI등재
      2013-01-01 평가 등재 1차 FAIL (등재유지) KCI등재
      2010-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2007-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2006-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2004-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.19 0.19 0.19
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.14 0.15 0.475 0
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼